Koo BS, Oh JS, Park SY, Shin JH, Ahn GY, Lee S, Joo KB, Kim TH. Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence. Ann Rheum Dis(IF:16.102;Q1). 2020 Oct;79(10):1327-1332. (2020)
https://pubmed.ncbi.nlm.nih.gov/32660979/

Lee TH, Koo BS, Nam B, Oh JS, Park SY, Lee S, Joo KB, Kim TH. Conventional disease-modifying antirheumatic drugs therapy may not slow spinal radiographic progression in ankylosing spondylitis: results from an 18-year longitudinal dataset. Ther Adv Musculoskelet Dis. 2020 Nov 28;12:1759720X20975912. doi: 10.1177/1759720X20975912. eCollection 2020. (2020)
https://pubmed.ncbi.nlm.nih.gov/33294039/

Jo S, Won EJ, Kim MJ, Lee YJ, Jin SH, Park PR, Song HC, Kim J, Choi YD, Kim JY, Shim SC, Choi SH, Park YS, Kim TH, Kim TJ. STAT3 Phosphorylation Inhibition for Treating Inflammation and New Bone Formation in Ankylosing Spondylitis. Rheumatology (Oxford) . 2020 Nov 25;keaa846. doi:10.1093/rheumatology/keaa846. Online ahead of print. (2020)
https://pubmed.ncbi.nlm.nih.gov/33237331/

Koo BS, Oh JS, Park SY, Shin JH, Ahn GY, Lee S, Joo KB,Kim TH.Response to ‘Correspondence on “Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence” by Zhanget al. Ann Rheum Dis(IF:16.102;Q1). 2020 Oct 1:annrheumdis-2020-218944. doi: 10.1136/annrheumdis-2020-218944. Online ahead of print. (2020)
https://pubmed.ncbi.nlm.nih.gov/33004327/

Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J; COAST-X Study Group. Ixekizumab Treatment in Patients with Non-Radiographic Axial Spondyloarthritis: Results of a 52-Week, Randomised, Placebo-Controlled Trial. Lancet. 2020 Jan 4;395(10217):53-64 (2020)
https://pubmed.ncbi.nlm.nih.gov/31813637/

van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019 Dec 7;394(10214):2108-2117 (2019)
https://pubmed.ncbi.nlm.nih.gov/31732180/

Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018 Sep;77(9):1295-1302 (2018)
https://pubmed.ncbi.nlm.nih.gov/29945918/